Recombinant Anti-EpCAM and Anti-CD3Human-mouse Chimeric Bispecific Antibody for Injection (Wuhan Yzy Biopharma Co Ltd) |
M-701 |
Phase 3 Clinical |
Wuhan Yzy Biopharma Co Ltd |
Ovarian Neoplasms; Solid tumours; Hydrothorax; Stomach Neoplasms; Neoplasms; Ascites; Colorectal Neoplasms; Pleural Effusion, Malignant; Carcinoma, Non-Small-Cell Lung |
Details
|
CD3 and B-cell maturation antigen T-cell engaging bispecific antibody (AbbVie/TeneoOne) |
ABBV-383; TNB-383B |
Phase 3 Clinical |
TeneoOne Inc |
Immunoglobulin Light-chain Amyloidosis; Multiple Myeloma |
Details
|
Brenetafusp |
PRAME HLA-A02; IMC-F106C |
Phase 3 Clinical |
Immunocore Ltd |
Solid tumours; Melanoma |
Details
|
Xaluritamig |
AMG-509 |
Phase 3 Clinical |
Xencor Inc, Amgen Inc |
Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Castration-Sensitive Prostate Neoplasms |
Details
|
AZD-0486 |
TNB-486; AZD-0486; AZD0486 |
Phase 3 Clinical |
Teneobio Inc |
Lymphoma, B-Cell; Leukemia, Lymphoid; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Lymphoma, Follicular; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
Anti-CD3/humanized 3F8 bispecific antibody-activated T lymphocytes (University of Virginia) |
|
Phase 2 Clinical |
University Of Virginia |
Neuroblastoma |
Details
|
Foralumab |
NI-0401/α-CD3; TZLS-401; NI-0401 |
Phase 2 Clinical |
Novimmune Sa, Medarex Inc |
Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus, Type 2; Lower Respiratory Tract Infections; Coronavirus Disease 2019 (COVID-19); Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Alzheimer Disease; Cognitive Dysfunction; Dementia; Crohn Disease |
Details
|
GNR-084 |
GNR-084 |
Phase 2 Clinical |
Generium Pharmaceuticals, Iontas |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
Anti-CD3 and anti-HER2 BiTE-expressing T cell (MedImmune) |
|
Phase 2 Clinical |
University Of Michigan, Huazhong University Of Science And Technology, University Of Virginia Cancer Center, Medimmune |
Breast Neoplasms |
Details
|
Vibecotamab |
XmAb-14045 |
Phase 2 Clinical |
Xencor Inc |
Leukemia, Myeloid; Myelodysplastic Syndromes; Blastic Plasmacytoid Dendritic Cell Neoplasm; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute |
Details
|
α/β CD3+/CD19+ cell depleted stem cell therapy (New York Medical College) |
|
Phase 2 Clinical |
New York Medical College |
Leukemia; Anemia; Thalassemia; Hodgkin Disease; Anemia, Aplastic; Lymphoma, Non-Hodgkin; Thrombocytopenia; Kostmann Syndrome; Anemia, Sickle Cell |
Details
|
MK-6070 |
HPN-328; MK-6070 |
Phase 2 Clinical |
Harpoon Therapeutics |
Small Cell Lung Carcinoma; Carcinoma, Neuroendocrine |
Details
|
Cibisatamab |
CEA-TCB; RG-7802; RO-6958688; CEA-CD3 TCB |
Phase 2 Clinical |
F. Hoffmann-La Roche Ltd |
Solid tumours; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
CD3/CD19 neg allogeneic BMT (National Institute of Allergy and Infectious Diseases/University of Pittsburgh) |
|
Phase 2 Clinical |
National Institute Of Allergy And Infectious Diseases (Niaid), University Of Pittsburgh |
Primary Immunodeficiency Diseases; Female Urogenital Diseases; Inflammation |
Details
|
MBS-303 |
MBS-303 |
Phase 2 Clinical |
Beijing Mabworks Biotech Co Ltd |
Lymphoma, B-Cell; Lymphoma, Non-Hodgkin |
Details
|
HBM-7022 |
HBM-7022; AZD-5863 |
Phase 2 Clinical |
Harbour Biomed |
Stomach Neoplasms; Esophageal Neoplasms; Neoplasms; Pancreatic Neoplasms; Esophageal adenocarcinoma; Carcinoma, Pancreatic Ductal |
Details
|
TAK-280 |
MVC-280; TAK-280 |
Phase 2 Clinical |
Maverick Therapeutics Inc |
Solid tumours; Neoplasms; Neoplasm Metastasis |
Details
|
GB-261 |
CND261; CND-261; GB-261 |
Phase 2 Clinical |
Genor Biopharma Co Ltd |
Lymphoma, B-Cell; Leukemia, Lymphoid; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
SAR-446309 |
AMX-818; HER2-XPAT; SAR-446309; VIR-5818 |
Phase 2 Clinical |
Amunix Pharmaceuticals Inc |
Solid tumours; Neoplasms |
Details
|
REGN-5459 |
REGN-5459 |
Phase 2 Clinical |
Regeneron Pharmaceuticals Inc |
Multiple Myeloma; Renal Insufficiency, Chronic |
Details
|
VNX-101 Gene Therapy (Vironexis Biotherapeutics) |
VNX-101 |
Phase 2 Clinical |
Vironexis Biotherapeutics Inc |
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
BCD-248 |
BCD-248 |
Phase 2 Clinical |
BIOCAD JSC |
Multiple Myeloma |
Details
|
Anti-CD3 x Anti-EGFR Bispecific Antibody (EGFRBi) Armed Fresh Peripheral Blood Mononuclear Cells therapy(University Of Virginia) |
|
Phase 2 Clinical |
University Of Virginia |
Pancreatic Neoplasms |
Details
|
CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells therapy(Institute Of Hematology & Blood Diseases Hospital) |
|
Phase 2 Clinical |
Institute Of Hematology & Blood Diseases Hospital |
Lymphoma, B-Cell |
Details
|
MDX-2001 |
MDX-2001; MDX2001 |
Phase 2 Clinical |
ModeX Therapeutics Inc |
Kidney Neoplasms; Biliary Tract Neoplasms; Head and Neck Neoplasms; Esophageal Neoplasms; Rectal Neoplasms; Stomach Neoplasms; Colonic Neoplasms; Pancreatic Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Thyroid Neoplasms; Endometrial Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms |
Details
|
IBI-3003 |
IBI3003; IBI-3003 |
Phase 2 Clinical |
Innovent Biologics(Suzhou) Co Ltd |
Multiple Myeloma |
Details
|
MBS-314 |
MBS-314 |
Phase 2 Clinical |
Beijing Mabworks Biotech Co Ltd |
Multiple Myeloma |
Details
|
Obrixtamig |
BI-764532; OBT620 |
Phase 2 Clinical |
C.H. Boehringer Sohn Ag & Co. Kg |
Small Cell Lung Carcinoma; Neoplasms; Neuroendocrine Tumors; Carcinoma, Neuroendocrine; Glioma |
Details
|
IMC-R117C |
IMC-R-117-C |
Phase 2 Clinical |
Immunocore Holdings PLC |
Stomach Neoplasms; Neoplasms; Pancreatic Neoplasms; Colorectal Neoplasms |
Details
|
GEN3017 |
GEN-3017 |
Phase 2 Clinical |
Genmab A/S |
Hematologic Neoplasms; Hodgkin Disease; Lymphoma, Non-Hodgkin |
Details
|
MP0533 |
MP0533 |
Phase 2 Clinical |
Molecular Partners Ag |
Leukemia, Myeloid, Acute |
Details
|
CD30 biAb-AATC(The Medical College Of Wisconsin Nonprofit) |
|
Phase 2 Clinical |
The Medical College Of Wisconsin Nonprofit |
Lymphoma, B-Cell; Leukemia; Hodgkin Disease; Lymphoma, Large-Cell, Anaplastic; Lymphoma; Lymphoma, T-Cell, Cutaneous |
Details
|
APVO-436 |
APVO-436; APVO436 |
Phase 2 Clinical |
Aptevo |
Myelodysplastic Syndromes; Leukemia, Myeloid, Acute |
Details
|
Emfizatamab |
GNC-038 |
Phase 2 Clinical |
SystImmune |
Solid tumours; Arthritis, Rheumatoid; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Extranodal NK-T-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, T-Cell; Lymphoma, Non-Hodgkin; Central Nervous System Lymphoma |
Details
|
CMD-011 |
CMD-011 |
Phase 2 Clinical |
Zhejiang Shimai Pharmaceutical Co Ltd |
Liver Neoplasms; Carcinoma, Hepatocellular |
Details
|
YK-012 |
YK012 |
Phase 2 Clinical |
Excyte Biopharma Ltd |
Lymphoma, B-Cell; Nephrosis; Lupus Erythematosus, Systemic; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
GEN-1047 |
GEN-1047 |
Phase 2 Clinical |
Genmab A/S |
Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
REGN-4336 |
REGN-4336 |
Phase 2 Clinical |
Regeneron Pharmaceuticals Inc |
Prostatic Neoplasms, Castration-Resistant |
Details
|
GR-1803 |
GR-1803 |
Phase 2 Clinical |
Chongqing Zhixiang Jintai Biopharmaceutical Co Ltd, Genrix (Shanghai) Biopharmaceutical Co Ltd |
Multiple Myeloma |
Details
|
CM-350 |
CM-350 |
Phase 2 Clinical |
Keymed Biosciences Co Ltd |
Solid tumours |
Details
|
1-A-46 |
BR-110; 1A46; 1-A-46; CMG1A46; CMG1A-46; BR110 |
Phase 2 Clinical |
Chengdu Chimagen Biosciences Co Ltd, Hisun Biopharmaceutical Co Ltd, BioRay Pharmaceutical Co Ltd |
Lymphoma, B-Cell; Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
LBL-034 |
LBL-034 |
Phase 2 Clinical |
Nanjing WeiLibo biological Technology Co Ltd |
Neoplasms; Multiple Myeloma |
Details
|
LBL-033 |
LBL-033 |
Phase 2 Clinical |
Nanjing WeiLibo biological Technology Co Ltd |
Neoplasms |
Details
|
CM-336(Connaught Biomedical Technology) |
CM-336; OM336 |
Phase 2 Clinical |
Keymed Biosciences Co Ltd |
Multiple Myeloma |
Details
|
ICP-B02 |
CM-355; ICP-B02 |
Phase 2 Clinical |
Beijing Tiannuo Jiancheng Pharmaceutical Technology Co Ltd, Keymed Biosciences Co Ltd |
Hematologic Neoplasms; Hematoma; Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
SMET-12 |
SMET-12 |
Phase 2 Clinical |
Zhejiang Shimai Pharmaceutical Co Ltd |
Solid tumours; Carcinoma, Non-Small-Cell Lung |
Details
|
TQB-2825 |
TQB-2825 |
Phase 2 Clinical |
Wuxi Biologics Co Ltd |
Lymphoma, B-Cell, Marginal Zone; Hematologic Neoplasms; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell |
Details
|
QLS-31905 |
QLS-31905 |
Phase 2 Clinical |
Qilu Pharmaceutical Co Ltd |
Solid tumours; Neoplasms |
Details
|
Nebratamig |
GNC-035 |
Phase 2 Clinical |
Sichuan Baili Pharmaceutical Co Ltd |
Solid tumours; Hematologic Neoplasms; Breast Neoplasms; Lymphoma, Non-Hodgkin; Metastatic breast cancer; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
TAK-186 |
EGFR x CD3 COBRA; MVC-101; TAK-186 |
Phase 2 Clinical |
Takeda Pharmaceutical Co Ltd |
Solid tumours; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
EMB-06 |
EMB-06; EMB06; CN106; CND106; CND-106 |
Phase 2 Clinical |
Shanghai Epimab Biotherapeutics, Inc |
Multiple Myeloma; Pemphigus |
Details
|
BNT-142 |
BNT-142 |
Phase 2 Clinical |
Biontech Se |
Solid tumours |
Details
|
CN-201 |
CN-201 |
Phase 2 Clinical |
Curon Biopharmaceutical Ltd |
Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Lymphoma, Non-Hodgkin |
Details
|
ZG006 |
ZG006; ZG-006 |
Phase 2 Clinical |
Gensun Biopharma Inc, Suzhou Zelgen Biopharmaceuticals Co Ltd |
Solid tumours; Small Cell Lung Carcinoma; Neoplasms; Carcinoma, Neuroendocrine |
Details
|
EX-103 |
EX-103; EX103 |
Phase 2 Clinical |
Guangzhou Excelmab Inc |
Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
Anti-CD3 monoclonal antibody (Jinan Tiankang Biological Products) |
|
Phase 2 Clinical |
Jinan Tiankang Biological Products Co Ltd |
Anemia, Aplastic |
Details
|
Cevostamab |
RG-6160; BFCR-4350A; RO-7187797 |
Phase 2 Clinical |
Genentech Inc |
Multiple Myeloma |
Details
|
Anti-CD3/anti-EGFR -activated T cells (Barbara Ann Karmanos Cancer Institute) |
|
Phase 2 Clinical |
Barbara Ann Karmanos Cancer Institute, University Of Virginia |
Glioblastoma; Pancreatic Neoplasms |
Details
|
Ubamatamab |
REGN-4018 |
Phase 2 Clinical |
Regeneron Pharmaceuticals Inc |
Ovarian Neoplasms; Neoplasms; Peritoneal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms |
Details
|
Anti-CD3-anti-HER2-activated T cells |
|
Phase 2 Clinical |
Transtarget |
Bone metastases; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Breast Neoplasms |
Details
|
JCAR-014 |
JCAR-014; JCAR021 |
Phase 2 Clinical |
Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center, Seattle Children'S Research Institute, Juno Therapeutics Inc |
Lymphoma, B-Cell; Leukemia; Leukemia, Lymphoid; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Candidiasis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Primary mediastinal B cell lymphoma; Leukemia, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma, Large-Cell, Anaplastic; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
A-319 |
A-319 |
Phase 1 Clinical |
Evive Biotech Ltd |
Lymphoma, B-Cell; Lupus Erythematosus, Systemic; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell |
Details
|
BCMA TriTAC |
HPN-217 |
Phase 1 Clinical |
Harpoon Therapeutics, Abbvie Inc |
Multiple Myeloma |
Details
|
Membrane bound ligand T-SIGn virus |
NG-348 |
Phase 1 Clinical |
Akamis Bio Ltd |
Neoplasms |
Details
|
Flotetuzumab |
S-80880; MGD-006; RES-234 |
Phase 1 Clinical |
Macrogenics Inc |
Hematologic Neoplasms; Leukemia; Leukemia, Myelogenous, Chronic; Leukemia, Hairy Cell; Mastocytosis, Systemic; Hodgkin Disease; Blastic Plasmacytoid Dendritic Cell Neoplasm; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Neoplasms, Plasma Cell; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute; Leukemia, Biphenotypic, Acute |
Details
|
NG-641 |
EnAd-FAP-BiTE; EnAd-FAP-Tac; NG-641; NG-aFAP |
Phase 1 Clinical |
Akamis Bio Ltd, University Of Oxford |
Squamous Cell Carcinoma of Head and Neck; Neoplasms, Glandular and Epithelial; Neoplasm Metastasis |
Details
|
Imvotamab |
IGM-2323 |
Phase 1 Clinical |
Igm Biosciences Inc |
Lymphoma, B-Cell, Marginal Zone; Myositis; Autoimmune Diseases; Lupus Erythematosus, Cutaneous; Lymphoma, Large B-Cell, Diffuse; Arthritis, Rheumatoid; Lupus Erythematosus, Systemic; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Arthritis |
Details
|
Vixtimotamab |
T-564; AMV-564 |
Phase 1 Clinical |
Amphivena Therapeutics Inc |
Solid tumours; Myelodysplastic Syndromes |
Details
|
MGD-014 |
MGD-014 |
Phase 1 Clinical |
Macrogenics Inc |
HIV Infections |
Details
|
JNJ-63898081 |
JNJ-8081; JNJ-63898081 |
Phase 1 Clinical |
Johnson & Johnson Innovative Medicine |
Neoplasms |
Details
|
K-193 |
K-193 |
Phase 1 Clinical |
Beijing Lvzhu Biological Technology Co Ltd |
Lymphoma, B-Cell |
Details
|
Anti-EGFR-bispecific antibody armed activated T-cell therapy (Memorial Sloan Kettering Cancer Center) |
|
Phase 1 Clinical |
Memorial Sloan Kettering Cancer Center |
Pancreatic Neoplasms |
Details
|
Runimotamab |
BTRC-4017A; RG-6194; RO-7227780 |
Phase 1 Clinical |
F. Hoffmann-La Roche Ltd |
Solid tumours |
Details
|
Autologous T-cell therapy (anti-PSMA-CD3), Roger Williams Medical Center |
|
Phase 1 Clinical |
Roger Williams Medical Center |
Prostatic Neoplasms |
Details
|
ONO-4685 |
ONO-4685 |
Phase 1 Clinical |
Merus Nv |
Lymphoma, T-Cell; Plaque psoriasis; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
M-802(Wuhan Yzy Biopharma/CSPC Pharmaceutical) |
M-802 |
Phase 1 Clinical |
Wuhan Yzy Biopharma Co Ltd, CSPC Pharmaceutical Group Ltd |
Solid tumours; Ovarian Neoplasms; Stomach Neoplasms; Breast Neoplasms |
Details
|
Emirodatamab |
AMG-427 |
Phase 1 Clinical |
Amgen Inc |
Leukemia, Myeloid, Acute |
Details
|
JNJ-63709178 |
JNJ-9178; CNTO-9958; JNJ-63709178 |
Phase 1 Clinical |
Johnson & Johnson Innovative Medicine, Genmab A/S |
Leukemia, Myeloid, Acute |
Details
|
SAR-442257 |
SAR-442257 |
Phase 1 Clinical |
Sanofi |
Neoplasms |
Details
|
CC-1 |
CC-1 |
Phase 1 Clinical |
University Of Tubingen, German Cancer Research Center (Dkfz) |
Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Carcinoma, Squamous Cell |
Details
|
Acapatamab |
AMG-160 |
Phase 1 Clinical |
Amgen Inc |
Prostatic Neoplasms, Castration-Resistant; Carcinoma, Non-Small-Cell Lung |
Details
|
Alnuctamab |
CC-93269; EM-901; BMS-986349 |
Phase 1 Clinical |
Engmab Ag |
Multiple Myeloma |
Details
|
Pavurutamab |
AMG-701 |
Phase 1 Clinical |
Amgen Inc |
Multiple Myeloma |
Details
|
HPN-536 |
HPN-536 |
Phase 1 Clinical |
Harpoon Therapeutics |
Neoplasms |
Details
|
CC-3 |
CC-3 |
Phase 1 Clinical |
Eberhard Karls University Of Tubingen, Germany |
Colorectal Neoplasms; Gastrointestinal Neoplasms |
Details
|
JS-203 |
JS-203 |
Phase 1 Clinical |
Shanghai Junshi Biological Engineering Co Ltd |
Lymphoma, B-Cell; Lymphoma, Non-Hodgkin |
Details
|
BC-004 |
BC-004 |
Phase 1 Clinical |
Shandong Buchang Pharmaceuticals Co Ltd |
Solid tumours; Breast Neoplasms |
Details
|
JY-016 |
JY-016 |
Phase 1 Clinical |
Beijing Jingyitaixiang Technology Development Co Ltd, Beijing Eastern Biotech Co Ltd |
Solid tumours; Colorectal Neoplasms; Lung Neoplasms |
Details
|
EX-105 |
EX-105; EX105 |
Phase 1 Clinical |
Guangzhou Excelmab Inc |
Solid tumours |
Details
|
EMB-07 |
EMB-07 |
Phase 1 Clinical |
Shanghai Epimab Biotherapeutics, Inc |
Solid tumours; Ovarian Neoplasms; Stomach Neoplasms; Triple Negative Breast Neoplasms; Adenocarcinoma of Lung; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms; Lymphoma; Uterine Neoplasms |
Details
|
BA-3182 |
BA-3182 |
Phase 1 Clinical |
Bioatla |
Solid tumours; Adenocarcinoma |
Details
|
BA-1202 |
BA-1202 |
Phase 1 Clinical |
Shandong Boan Biotechnology Co Ltd |
Solid tumours |
Details
|
NexGem |
CLN-978 |
Phase 1 Clinical |
Adimab LLC |
Lupus Erythematosus, Systemic; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
MGD-024 |
MGD-024 |
Phase 1 Clinical |
Macrogenics Inc |
Leukemia, Myelogenous, Chronic; Leukemia, Hairy Cell; Hodgkin Disease; Myelodysplastic Syndromes; Neoplasms; Blastic Plasmacytoid Dendritic Cell Neoplasm; Leukemia, B-Cell; Leukemia, Myeloid, Acute |
Details
|
Cabotamig |
ARB-202 |
Phase 1 Clinical |
Arbele Corp |
Liver Neoplasms; Biliary Tract Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal adenocarcinoma; Gastrointestinal Neoplasms |
Details
|
CX-904 |
CX-904 |
Phase 1 Clinical |
Amgen Inc, Cytomx Therapeutics Inc |
Solid tumours; Neoplasms |
Details
|
CLN-049 |
CLN-049 |
Phase 1 Clinical |
University Of Tubingen, German Cancer Research Center (Dkfz) |
Myelodysplastic Syndromes; Leukemia, Myeloid, Acute |
Details
|
XmAb-819 |
XmAb-819 |
Phase 1 Clinical |
Xencor Inc |
Kidney Neoplasms; Carcinoma, Renal Cell |
Details
|
NILK-2301 |
NILK-2301; NI-2301 |
Phase 1 Clinical |
Novimmune Sa |
Solid tumours; Colorectal Neoplasms |
Details
|
BGB-B455 |
BGB-B455 |
Phase 1 Clinical |
BeOne Medicines Ltd |
Solid tumours |
Details
|
ABO-2203 |
ABO2203; ABO-2203 |
Phase 1 Clinical |
Ruijin Hospital |
Autoimmune Diseases |
Details
|
JNJ-70218902 |
JNJ-70218902 |
Phase 1 Clinical |
Johnson & Johnson Innovative Medicine |
Solid tumours; Neoplasms; Myelodysplastic Syndromes; Prostatic Neoplasms, Castration-Resistant; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
APTN-101 |
APTN 101 |
Phase 1 Clinical |
Adaptin Bio |
Glioblastoma |
Details
|
ALPS-12 |
ALPS12; RG6524; RG-6524; ALPS 12 |
Phase 1 Clinical |
Chugai Pharmaceutical Co Ltd |
Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Neuroendocrine |
Details
|
GS-8588 |
GS-8588 |
Phase 1 Clinical |
Gilead Sciences Inc |
HIV Infections |
Details
|
GNC-077 |
GNC-077; GNC077 |
Phase 1 Clinical |
Baili-Bio (Chengdu) Pharmaceutical Co Ltd |
Solid tumours; Breast Neoplasms; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms |
Details
|
Mesothelin x CD3 Bispecific Antibody(Integral Molecular) |
LNK-101; CT-95; LNK101 |
Phase 1 Clinical |
Integral Molecular Inc |
Solid tumours; Pancreatic Neoplasms; Neoplasms; Carcinoma, Ovarian Epithelial; Mesothelioma; Cholangiocarcinoma; Neoplasm Metastasis |
Details
|
CM-380 |
CM380; CM-380 |
Phase 1 Clinical |
Keymed Biosciences Co Ltd |
Multiple Myeloma |
Details
|
QL-335 |
QL335; QL-335 |
Phase 1 Clinical |
Qlsf Biotherapeutics Inc |
Colorectal Neoplasms |
Details
|
LNF-2007 |
LNF2007; LNF-2007 |
Phase 1 Clinical |
Shandong New Time Pharmaceutical Co Ltd |
Solid tumours |
Details
|
QL-325 |
QL-325 |
Phase 1 Clinical |
Qilu Pharmaceutical Co Ltd, Qlsf Biotherapeutics Inc |
Leukemia, Myeloid, Acute |
Details
|
JNJ-67571244 |
JNJ-67571244; JNJ-67371244; JNJ-1244 |
Phase 1 Clinical |
Johnson & Johnson |
Myelodysplastic Syndromes; Leukemia, Myeloid, Acute |
Details
|
CTIM-76 |
CTIM-76 |
Phase 1 Clinical |
Integral Molecular Inc |
Ovarian Neoplasms; Solid tumours; Neoplasms; Testicular Neoplasms; Endometrial Neoplasms |
Details
|
YKST-02 |
YKST02; YKST-02 |
Phase 1 Clinical |
Excyte Biopharma Ltd |
Multiple Myeloma |
Details
|
SCTB-35 |
SCTB35; SCTB-35 |
Phase 1 Clinical |
SinoCelltech Ltd |
Lymphoma, B-Cell; Autoimmune Diseases; Lupus Erythematosus, Systemic |
Details
|
JNJ-87890387 |
JNJ-87890387 |
Phase 1 Clinical |
Janssen Research & Development Llc |
Solid tumours |
Details
|
XmAb-541 |
XmAb541; XmAb-541 |
Phase 1 Clinical |
Xencor Inc |
Ovarian Neoplasms; Ovarian germ cell tumor; Endometrial Neoplasms; Germinoma; Neoplasms, Germ Cell and Embryonal |
Details
|
[89Zr]Zr-BI-764532 |
|
Phase 1 Clinical |
C.H. Boehringer Sohn Ag & Co. Kg, Boehringer Ingelheim Gmbh |
Small Cell Lung Carcinoma; Carcinoma, Neuroendocrine |
Details
|
TGI-6 |
TGI-6 |
Phase 1 Clinical |
Hefei TG ImmunoPharma Co Ltd |
Solid tumours; Colorectal Neoplasms |
Details
|
SIM-0500 |
SIM0500; SIM-0500 |
Phase 1 Clinical |
Simcere Pharmaceutical Group Ltd |
Bone Marrow Neoplasms; Multiple Myeloma |
Details
|
Recombinant anti BCMA/CD3 bispecific antibody(Hualan Genetic Engineering) |
|
Phase 1 Clinical |
Hualan Genetic Engineering (Henan) Co Ltd |
Multiple Myeloma |
Details
|
Oncolytic Virus R130(Yunying Medical) |
R130; R-130; R-130-OV |
Phase 1 Clinical |
Shanghai Yunying Medical Technology Co Ltd |
Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms; Melanoma; Pharyngeal Neoplasms; Laryngeal Neoplasms; Fallopian Tube Neoplasms; Lung Neoplasms; Bone Neoplasms; Colorectal Neoplasms; Genital Neoplasms, Female; Peritoneal Neoplasms; Sarcoma; Osteosarcoma; Kidney Neoplasms; Breast Neoplasms; Otorhinolaryngologic Neoplasms; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Nose Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma; Solid tumours; Liver Neoplasms; Carcinoma, Bronchogenic; Ovarian Neoplasms; Head and Neck Neoplasms |
Details
|
QLS-32015 |
QLS-32015; QLS32015 |
Phase 1 Clinical |
Qilu Pharmaceutical Co Ltd |
Multiple Myeloma |
Details
|
SAIL-66 |
SAIL-66; SAIL66 |
Phase 1 Clinical |
Chugai Pharmaceutical Co Ltd |
Solid tumours |
Details
|
IMC-P115C |
IMC-P-115-C; PRAME-HLE-A02 |
Phase 1 Clinical |
Immunocore Holdings PLC |
Ovarian Neoplasms; Solid tumours; Small Cell Lung Carcinoma; Sarcoma, Synovial; Sarcoma, Endometrial Stromal; Carcinoma, Adenoid Cystic; Cholangiocarcinoma; Endometrial Neoplasms; Uterine Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma |
Details
|
BR-115 |
CMG6A19; BR115; BR-115; CMG-6-A-19 |
Phase 1 Clinical |
Chengdu Chimagen Biosciences Co Ltd |
Solid tumours |
Details
|
OBT620 |
OBT620 |
Phase 1 Clinical |
Boehringer Ingelheim Gmbh, Oxford Biotherapeutics Ltd |
Small Cell Lung Carcinoma |
Details
|
CBA-1535 |
CBA-1535 |
Phase 1 Clinical |
Chiome Bioscience Inc |
Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Mesothelioma; Carcinoma, Non-Small-Cell Lung |
Details
|
JANX-008 |
EGFR-TRACTr; JANX008; JANX-008 |
Phase 1 Clinical |
Janux Therapeutics Inc |
Solid tumours; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung |
Details
|
ZW-171 |
ZW-171 |
Phase 1 Clinical |
Zymeworks Inc |
Solid tumours; Neoplasms |
Details
|
JANX-007 |
JANX-007; PSMA-TRACTr |
Phase 1 Clinical |
Janux Therapeutics Inc |
Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms |
Details
|
TQB-2934 |
TQB2934; TQB-2934 |
Phase 1 Clinical |
Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group |
Multiple Myeloma |
Details
|
JNJ-80948543 |
JNJ-80948543 |
Phase 1 Clinical |
Janssen Research & Development Llc |
Lymphoma, B-Cell; Neoplasms; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
PIT-565 |
PIT-565 |
Phase 1 Clinical |
Novartis Pharma Ag |
Lymphoma, B-Cell; Neoplasms; Lupus Erythematosus, Systemic; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
CC-312 |
CC-312 |
Phase 1 Clinical |
CytoCares (Shanghai) Inc |
Hematologic Neoplasms; Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
ASP-2138 |
ASP-2138 |
Phase 1 Clinical |
Astellas Pharma Global Development Inc, Xencor Inc |
Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms |
Details
|
ISB-2001 |
ISB-2001 |
Phase 1 Clinical |
Ichnos Sciences Sa |
Multiple Myeloma |
Details
|
GR-1901 |
GR1901; GR-1901 |
Phase 1 Clinical |
Chongqing Zhixiang Jintai Biopharmaceutical Co Ltd, Genrix (Shanghai) Biopharmaceutical Co Ltd |
Leukemia, Myeloid, Acute |
Details
|
QLS-31904 |
QLS31904; QLS-31904 |
Phase 1 Clinical |
Qilu Pharmaceutical Co Ltd |
Solid tumours |
Details
|
RO-7428731 |
RO-7428731; RG-6156 |
Phase 1 Clinical |
F. Hoffmann-La Roche Ltd |
Glioblastoma |
Details
|
NM32-2668 |
NM-32-2668 |
Phase 1 Clinical |
Numab Therapeutics Ag |
Leiomyosarcoma; Carcinoma, Renal Cell; Esophageal Neoplasms; Adenocarcinoma of Lung; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Neoplasms; Liposarcoma; Mesothelioma; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Endometrial Neoplasms; Adenocarcinoma; Melanoma |
Details
|
GBR-1342 |
GBR-1342; ISB-1342 |
Phase 1 Clinical |
Glenmark Pharmaceuticals Ltd |
Multiple Myeloma |
Details
|
Recombinant humanized anti-CD19/CD3 bispecific antibody(New Time Pharmaceutical) |
LNF-1904 |
Phase 1 Clinical |
Shandong New Time Pharmaceutical Co Ltd |
Lymphoma, B-Cell; Leukemia, B-Cell |
Details
|
XmAb-968 |
XmAb968 |
Phase 1 Clinical |
Xencor Inc |
Hematologic Neoplasms; Leukemia, Promyelocytic, Acute |
Details
|
XmAb-18968 |
XmAb-18968 |
Phase 1 Clinical |
The Medical College Of Wisconsin Nonprofit |
Leukemia, Myeloid, Acute |
Details
|
SQZ-622(Novartis Pharma) |
SQZ-622 |
Phase 1 Clinical |
Novartis Pharma Ag |
Leukemia, Myeloid, Acute |
Details
|
Forimtamig |
RG-6234 |
Phase 1 Clinical |
F. Hoffmann-La Roche Ltd |
Multiple Myeloma |
Details
|
RG-6232 |
RG-6232 |
Phase 1 Clinical |
F. Hoffmann-La Roche Ltd |
Melanoma |
Details
|
RG-6007 |
RO-7283420; RG-6007 |
Phase 1 Clinical |
F. Hoffmann-La Roche Ltd |
Leukemia, Myeloid, Acute |
Details
|
SAR-443216 |
SAR-443216 |
Phase 1 Clinical |
Sanofi |
Solid tumours; Stomach Neoplasms; Neoplasms; Breast Neoplasms; Lung Neoplasms |
Details
|
Recombinant oncolytic type II herpes simplex virus (Binhui Biopharmaceutical) |
BS-006; oHSV2-BiTEs; oHSV2CD3-PD-L1 |
Phase 1 Clinical |
Wuhan Binhui Biotechnology Co Ltd |
Solid tumours; Neoplasms; Melanoma; Uterine Cervical Neoplasms |
Details
|
JNJ-78306358 |
JNJ-78306358; JNJ-6358 |
Phase 1 Clinical |
Janssen Research & Development Llc |
Solid tumours |
Details
|
TNB-585 |
TNB-585; AMG-340 |
Phase 1 Clinical |
Teneobio Inc |
Prostatic Neoplasms, Castration-Resistant |
Details
|
BC-3448 |
BC3448; BC-3448 |
Phase 1 Clinical |
Wuxi BioCity |
Solid tumours |
Details
|
IBI-389 |
IBI-389 |
Phase 1 Clinical |
Innovent Biologics(Suzhou) Co Ltd |
Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Neoplasms; Pancreatic Neoplasms |
Details
|
hEGFRvIII-CD3 Bi-scFv |
|
Phase 1 Clinical |
Duke University |
Glioblastoma; Glioma |
Details
|
JNJ-78278343 |
|
Phase 1 Clinical |
Janssen Research & Development Llc |
Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms |
Details
|
RGV-004 |
RGV-004 |
Phase 1 Clinical |
Hangzhou Rongu Biotechnology Co Ltd |
Lymphoma, B-Cell |
Details
|
Recombinant humanized anti-BCMA/CD3 bispecific antibody(New Time Pharmaceutical) |
|
Phase 1 Clinical |
Shandong New Time Pharmaceutical Co Ltd |
Multiple Myeloma |
Details
|
NVG-111 |
NVG-111 |
Phase 1 Clinical |
NovalGen Ltd |
Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Melanoma; Carcinoma, Non-Small-Cell Lung |
Details
|
BI-765049 |
BI-765049; OBT-624 |
Phase 1 Clinical |
Oxford Biotherapeutics Ltd |
Solid tumours |
Details
|
GNC-039 |
GNC-039 |
Phase 1 Clinical |
Sichuan Baili Pharmaceutical Co Ltd |
Solid tumours; Hematologic Neoplasms; Glioma; Neoplasm Metastasis |
Details
|
RO-7425781 |
RO-7425781 |
Phase 1 Clinical |
F. Hoffmann-La Roche Ltd |
Multiple Myeloma |
Details
|
RO-7293583 |
RO-7293583 |
Phase 1 Clinical |
F. Hoffmann-La Roche Ltd |
Skin Melanoma; Uveal melanoma; Melanoma |
Details
|
Rezetamig |
JNJ-8780; JNJ75348780; JNJ-75348780 |
Phase 1 Clinical |
Teneobio Inc |
Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
Y-150(Wuhan Yzy Biopharma/CSPC Pharmaceutical) |
Y-150; Y150 |
Phase 1 Clinical |
Wuhan Yzy Biopharma Co Ltd, CSPC Pharmaceutical Group Ltd |
Multiple Myeloma |
Details
|
EX-101 |
EX-101; EX101 |
Phase 1 Clinical |
Guangzhou Excelmab Inc |
Solid tumours |
Details
|
Plamotamab |
XmAb-13676 |
Phase 1 Clinical |
Xencor Inc |
Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
A-337 |
A-337 |
Phase 1 Clinical |
Evive Biotech Ltd |
Solid tumours; Neoplasms |
Details
|
CCW-702 |
CCW-702 |
Phase 1 Clinical |
The Scripps Research Institute Inc, Abbvie Inc |
Prostatic Neoplasms |
Details
|
ERY-974 |
ERY-974 |
Phase 1 Clinical |
Chugai Pharmaceutical Co Ltd |
Solid tumours; Carcinoma, Hepatocellular |
Details
|
PCART7-CD3 |
PCART7-CD3 |
Clinical |
National University Of Singapore |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
InHeAb-01 |
InHeAb-01; bsAB |
Clinical |
University Hospital Tuebingen |
Neoplasms |
Details
|